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Abstract
Objectives: Aspergillus sensitization is important for patients with asthma. In Japan, the methods applied to
measure allergen-specific immunoglobulin E (IgE) levels in blood are the single antigen test, ImmunoCAP (IC), and
multiple antigen simultaneous tests, View Allergy® (VA) or MAST IV® (MA). Here, we report the concordance rates
(CR) for Aspergillus-specific IgE levels between IC and VA or MA.
Methods: Aspergillus-specific IgE levels in serum samples from 34 male and 23 female patients with bronchial
asthma were measured by ImmunoCAP, View Allergy® (both Thermo Fisher Scientific, Uppsala, Sweden) and MAST
IV® (Hitachi Chemical Diagnostics, Inc. Mountain View, CA, USA). Results of Class 1 or greater were regarded as
positive, and the CRs between the methods were assessed.
Results: Of the 57 patients, 24 were found to be positive for Aspergillus-specific IgE by IC, and 5 had allergic
bronchopulmonary aspergillosis (ABPA). Significant intraclass correlations were observed between IC and VA
(r=0.964, p<0.001) and between IC and MA (r=0.620, p<0.001). Between IC and VA, the CR, positive concordance
ratio, and negative concordance ratio was 98.2%, 100%, and 96.9%, respectively; between IC and MA, these values
were 77.2%, 45.8%, and 100%, respectively. All five patients with ABPA were found to be positive for Aspergillus-
specific IgE by VA, whereas only three of these patients (60%) were found to be positive by MA.
Conclusions: In patients with asthma, measurements obtained by IC were more concordant with those obtained by
VA compared with those obtained by MA.
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Introduction
In Japan, the mortality from bronchial asthma (BA) was 4.5%–
5.0% per 100,000 individuals between 1975 and 1994. Mortality
from BA began to decrease in 1997 and reached 1.2 per 100,000
population (1,510 deaths) in 2015.1 However, some patients still
suffer from poorly controlled asthma. According to a report from
the Netherlands, 3.6% of adult patients with asthma are classified
as having severe refractory asthma despite adequate adherence
to treatment with inhaled corticosteroids and long-acting
bronchodilators with correct inhalation technique.2 In this
circumstance, the assessment and treatment of patients with
refractory asthma is an extremely important issue for the
therapeutic management of BA.
In addition to well-known risk factors for refractory asthma,
such as obesity and gastroesophageal reflux, fungal sensitization
can also induce this condition, as was recently proposed in the
concept of severe asthma with fungal sensitization (SAFS).3
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Sensitization to fungi is thought to lead to the development of
refractory BA, and sensitization to Aspergillus is particularly
common. Because several studies have demonstrated that
sensitization of immunoglobulin E (IgE) to Aspergillus fumigatus
is a risk factor for reduction and acute deterioration of pulmonary
function,4,5 caution should be taken to detect the development of
allergic bronchopulmonary aspergillosis (ABPA) during treatment
of refractory asthma. In Japan, because several epidemiological
studies have shown that approximately 10% of patients with
asthma are sensitized to A. fumigatus,6,7 early and correct
recognition of sensitization to Aspergillus is also important for
management of patients with asthma.
Although sensitization to Aspergillus can be determined by
blood or skin tests, the blood test is more frequently conducted
to measure Aspergillus-specific IgE levels because of its
simplicity and minimal invasiveness. ImmunoCAP (IC) is
commonly performed to measure allergen-specific IgE levels
owing to the large quantity of accumulated data on this assay.8
However, because the IC is a single-antigen test, a multiple
antigen simultaneous test is often applied to measure allergen-
specific IgE levels in daily clinical practice. At present, allergen-
specific IgE multiple antigen simultaneous tests are performed in
Japan using either MAST IV® (MA) or VIEW Allergy® (VA). The
initial version of the MAST kit allowed the measurement of only
16 allergen types, but the MAST IV®, which includes Aspergillus
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 as a test item, was recently released. Additionally, VA, a new
multiple allergen-specific IgE assay, was released in 2016. VA is
sold by the same manufacturer and includes the same antigen as
IC.9
MA and IC are different in terms of the applied measurement
principle, so the results were assessed after class conversion.
The measurement principles of these three test methods are
shown in Table 1. In the present study, because previous studies
reported that measurements obtained by MA sometimes do not
agree with those obtained by IC, we assessed the concordance
rates of Aspergillus-specific IgE levels between the IC and the
newly available multiple antigen simultaneous test methods, i.e.,
VA and MA.
Methods
We used serum samples obtained from 57 patients with BA
who visited Fujita Health University Second Teaching Hospital
between February and September 2017 and provided consent to
participate in this study. The diagnosis of BA was made by
pulmonologists according to the 2015 Japanese Asthma
Prevention and Management Guidelines,10 and the treatment
level required for each patient was classified according to the
2017 Global Initiative for Asthma (GINA) guidelines.11 ABPA was
defined as a condition that was diagnosed by pulmonologists
according to the Patterson criteria12 and that presented with
chest imaging findings of central bronchodilatation and
infiltration. This study was conducted after review and approval
by the Medical Research Ethics Committee of Fujita Health
University (Approval No. HM16-371).
The Aspergillus-specific IgE levels in the serum samples were
measured separately by IC, VA, and MA. Measurement of
Aspergillus-specific IgE antibody levels by IC and VA was
outsourced to Thermo Fisher Diagnostic K.K., and measurement
by MA was outsourced to testing centers (BML, Inc. and SRL,
Inc.). Results of Class 1 or greater, as determined by IC, MA, and
VA, were regarded as positive, and concordance rates of IC with
MA and VA were assessed. The class conversion table for each
test method is shown in Table 2.
The statistical analysis software used was StatMate version
3.19 (ATMS, Co., Ltd., Tokyo, Japan). Two independent groups
were compared by the Mann‒Whitney U test. The degree of
association between two variables was determined using
Spearman’s rank correlation coefficients. Differences across
three or more independent groups were assessed by the
Kruskal‒Wallis test. Values of p<0.05 were considered to
indicate a statistically significant difference.
Results
This study included 34 men (mean±standard deviation for age:
57.5±20.77 years) and 23 women (49.8±15.07 years). Of the 57
patients, 8 (14.0%), 6 (10.5%), 24 (42.1%), 11 (19.2%), and 8
(14.0%) were assessed as needing Step 1, 2, 3, 4, and 5 treatment
levels, respectively, based on the guidelines set by GINA. The
median disease duration was 12 years (Q1–Q3: 3–30 years). The
median total IgE level was 520 IU/mL (Q1–Q3: 172–1538 IU/mL)
(Table 3). Of the 57 patients, 24 (42.1%) were found to be
positive for Aspergillus-specific IgE by IC. This group included 5
patients with ABPA. The measurements obtained by IC were
significantly correlated with those obtained by both VA (r=0.976,
p<0.001) and MA (r=0.635, p<0.001). All 5 patients with ABPA
(n=5/5) were found to be positive for Aspergillus-specific IgE by
VA, whereas 60% (n=3/5) were found to be positive by MA
(Figure 1). Between IC and VA, the concordance rate was 98.2%,
the positive concordance ratio was 100%, and the negative
concordance ratio was 96.9%. Between IC and MA, the
concordance rate was 77.2%, the positive concordance ratio was
45.8%, and the negative concordance ratio was 100% (Figure 2).
Discussion
The antibody class IgE was first reported by Ishizaka et al. in
1967,13 and IC has been widely used for measuring allergen-
specific IgE levels for more than 40 years. IC is regarded as the
gold standard for the in vitro measurement of allergen-specific
IgE levels.8 Thus, IC results are used as the benchmark against
which the results of screening for allergen-specific IgE are
compared.
This study found that, in patients with BA, Aspergillus-specific
IgE levels measured by IC were more concordant with those
Table 2 Patient background
Asthma Patient
Age (years), mean±SD 54.5±19.0
Gender (male:female), n (%) 34 (60%):23 (40%)
GINA treatment step, n (1:2:3:4:5) 8:6:24:11:8
Duration of asthma (years), median (IQR) 12 (3–30)
Total IgE (IU/mL), median (IQR)* 520 (172–1538)
BA: bronchial asthma, IQR: interquartile range, SD: standard deviation
* The same serum as used in this study.
Table 3 Class conversion table for ImmunoCAP, View Allergy®, and
MAST IV®
Class ImmunoCAP(UA/mL)
View allergy®
(Index)
MAST IV®
(LC)
6 ≧100.0 ≧29.31 160–200
5 50.00–99.99 17.35–29.30 120–159
4 17.5–49.99 7.05–17.34 58.1–119
3 3.50–17.49 1.80–7.04 13.5–58.0
2 0.70–3.49 0.50–1.79 2.78–13.4
1 0.35–0.69 0.27–0.49 1.40–2.77
0 0–0.34 0–0.26 0–1.39
LC: lumicount
Table 1 Comparison of inspection methods
ImmunoCAP View Allergy® MAST IV®
Manufacturer Thermo Fisher Diagnostics, Ltd. Thermo Fisher Diagnostics, Ltd. Hitachi Chemical Co., Ltd.
Measurement principle FEIA FEIA CLEIA
Results UA/mL Class (0–6) Class (0–6)
FEIA: Fluorescence Enzyme Immunoassay
CLEIA: Chemiluminescent Enzyme Immunoassay
Fujita Medical Journal 2018 Volume 4 Issue 3
67
measured by VA than with those measured by MA. The higher
concordance rate between IC and VA is presumably attributable
to the fact that both test methods were developed by the same
manufacturer and use the same antigen.9 Unfortunately, we could
not obtain information on the Aspergillus strain used for MA.
Because it has been reported that fungal antigen components are
likely to differ among culture methods, deviations in the test
results were assumed to be attributable to differences in the
antigen components of the test kits and the inactivation of
antigens during test kit production.14
Of the five patients with ABPA, 60% (3/5) were identified as
positive for Aspergillus-specific IgE by MA, whereas VA identified
all ABPA patients (5/5) as positive. A recent report indicated that
many patients with ABPA are sensitized to Asp f 1 and Asp f 2,
based on component analysis.15 The differing sensitivity of the
MA and VA tests for patients with ABPA may be attributable to
Figure 1 The degree of association between two variables was determined using Spearman’s rank correlation coefficients. Association of Aspergillus-
specific immunoglobulin E classes determined by ImmunoCAP with those determined by VIEW Allergy and MAST IV. The numerical values in cells are
the number of patients. ImmunoCAP showed significant correlations with both test methods. Of the 5 patients with allergic bronchopulmonary
aspergillosis included in this study, 5 were found to be positive by VIEW Allergy, and 3 were found to be positive by MAST IV.
*; Including 1 ABPA patient, **; Including 2 ABPA patients
Figure 2 Concordance rates, positive concordance ratios, and negative concordance ratios of Aspergillus-specific immunoglobulin E levels between
ImmunoCAP and VIEW Allergy and between ImmunoCAP and MAST IV. The numerical values in cells are the number of patients.
CR; concordance rate, PCR; positive concordance ratio, NCR; negative concordance ratio
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differences in the content of these components.
For optimal management of patients with asthma, it is
important to determine whether they are sensitized to inhalant
antigens, such as fungi, mites, and pollen. The allergen-specific
IgE multiple antigen simultaneous test is widely applied in
clinical practice because it allows the examination of
sensitizations to a wide range of antigens, including not only
inhalant antigens but also food antigens and latex. Recently, it has
become increasingly important to clarify Aspergillus sensitization
in asthma patients, and the screening method used in the initial
phase of asthma treatment requires a high level of sensitivity.
Based on reports demonstrating an increase in Aspergillus-
specific IgE during medical treatment and occasional ABPA
development during asthma treatment,16,17 Aspergillus-specific
IgE should be monitored over time in the treatment of asthma,
and it is therefore important to confirm Aspergillus sensitization
in ABPA diagnosis.
When a simultaneous multi-parameter screening of allergen-
specific IgE is used to determine the sensitization status of a BA
patient, it is important to consider that the results may not be
consistent among tests. This difference is clinically relevant
because the gold standard Immuno CAP, rather than the initial
screening method, is often used for IgE measurement during
asthma management. Our results indicate that VA, which
achieved consistent results in comparison with historical data and
exhibited a high sensitivity even in ABPA patients, is superior as
a screening method for assessing Aspergillus sensitization in
asthma patients.
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